| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|--------------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | \| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Ziopharm | | | | | | | | | ...

ET ZIOPHARM Oncology, Inc. (ZIOP) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Adam Levy - Executive Vice President, Investor Relations and Corporate Laurence Cooper - Chief Executive Officer Heidi Hagen - Interim Chief Executive Officer Raffaele Baffa - Chief Medical Officer James Huang - Conference Call Participants Alethia Young - Cantor Fitzgerald Chris Howerton - Jefferies Yale Jen - Laidlaw & Co Thomas Flaten - Lake Street Capital Markets David Novak - Raymond Ja ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-----------------------------------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | \| | | | | | | | | | | | | | | | | | | ...

Company Overview 1 November 19, 2020 O N C O L O G Y www.ziopharmforward.com Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm Oncology, Inc. ("Ziopharm") management and expectations as to and beliefs about the consent solicitation (the "Consent Solicitation") initiated by WaterMill A ...

Third Quarter 2020 Financial Results and Update 05 November 2020 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's ...

ZIOPHARM Oncology, Inc. (ZIOP) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Laurence Cooper - Chief Executive Officer Sath Shukla - Chief Financial Officer Adam Levy - Executive Vice President, Investor Relations and Corporate Communications Conference Call Participants Yale Jen - Laidlaw & Company Alethia Young - Cantor David Novak - Raymond James Thomas Flaten - Lake Street Capital Partners ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1475642 (State or other jurisdiction of in ...

ZIOPHARM Oncology, Inc. (ZIOP) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Chris Taylor - VP, IR and Corporate Communications Laurence Cooper - CEO Sath Shukla - CFO Conference Call Participants Chris Howerton - Jeffries Thomas Flaten - Lake Street Capital Markets Yale Jen - Laidlaw & Company Operator Greetings, and welcome to the ZIOPHARM Oncology Second Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer ...

Second Quarter 2020 Financial Results and Update 06 August 2020 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's b ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1475642 (State or other jurisdiction of incorpor ...